SCM
NPCE icon

Sterling Capital Management’s Neuropace NPCE Stock Holding History

Sterling Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48K Sell
93
-63
-40% -$1.01K ﹤0.01% 3060
2026
Q1 		$2.05K Hold
156
– – ﹤0.01% 2990
2025
Q4 		$2.41K Buy
156
+98
+169% +$1.31K ﹤0.01% 3044
2025
Q3 		$598 Hold
58
– – ﹤0.01% 3142
2025
Q2 		$646 Buy
58
+44
+314% +$550 ﹤0.01% 3124
2025
Q1 		$172 Hold
14
– – ﹤0.01% 3103
2024
Q4 		$157 Hold
14
– – ﹤0.01% 3140
2024
Q3 		$98 Buy
+14
New +$102 ﹤0.01% 3192

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sterling Capital Management's NPCE Position: Q2 2026 in Review

Sterling Capital Management reduced its Neuropace (NPCE) stake by 40% in Q2 2026, selling an estimated $1.01K and leaving 93 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Sterling Capital Management first reported a position in NPCE in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.41K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Sterling Capital Management held 93 shares of Neuropace worth $1.48K as of Q2 2026.
  • Sterling Capital Management sold 63 Neuropace shares in Q2 2026, an estimated $1.01K.
  • Neuropace made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3060 holding.
  • Sterling Capital Management first reported a position in Neuropace in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Neuropace position peaked at $2.41K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.